Bristol Myers Squibb Announces Data From Three Studies On Breyanzi For Large B-Cell Lymphoma, Mantle Cell Lymphoma, And Follicular Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb (BMY) has announced data from three studies on Breyanzi, targeting large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. The results could impact the company's stock performance.
June 03, 2024 | 2:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb has announced data from three studies on Breyanzi, which could influence the stock price based on the results' reception.
The announcement of data from three studies on Breyanzi could positively impact BMY's stock price if the results are favorable, as it demonstrates progress in their oncology pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100